COST-EFFECTIVENESS ANALYSIS OF PATIROMER IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION FOR THE TREATMENT OF HYPERKALEMIA: ANALYSIS OF THE DIAMOND CLINICAL TRIAL

被引：0
|
作者：
Stawowczyk, E. [1 ]
Turner, M. [1 ]
Lewis, R. D. [1 ]
Lloyd, I. T. [1 ]
Ruiz, O. [2 ]
Serna, Ramirez De Arellano A. [3 ]
机构：
[1] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[2] CSL Vifor, Barcelona, Spain
[3] CSL Vifor, Zurich, Switzerland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE457
引用
收藏
页码：S139 / S139
页数：1
相关论文
共 50 条
  • [31] ASSESSING THE COST-EFFECTIVENESS OF PATIROMER PLUS SPIRONOLACTONE THERAPY IN HEART FAILURE PATIENTS WITH HYPERKALEMIA
    Bounthavong, M.
    Butler, J.
    Dolan, C. M.
    Dunn, J. D.
    Fisher, K. A.
    Oestreicher, N.
    Pitt, B.
    Hauptman, P. J.
    Veenstra, D. L.
    VALUE IN HEALTH, 2017, 20 (05) : A271 - A271
  • [32] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION IN SINGAPORE
    Declan, L.
    Tang, Z. X.
    Ng, C.
    Tan, J.
    Trueman, D.
    Woodcock, F.
    Cristino, J.
    VALUE IN HEALTH, 2018, 21 : S106 - S106
  • [33] Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
    Yao, Younan
    Zhang, Rongcheng
    An, Tao
    Zhao, Xinke
    Zhang, Jian
    ESC HEART FAILURE, 2020, 7 (06): : 3582 - 3592
  • [34] Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction
    Sandhu, Alexander T.
    Ollendorf, Daniel A.
    Chapman, Richard H.
    Pearson, Steven D.
    Heidenreich, Paul A.
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (10) : 681 - +
  • [35] Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia (vol 36, pg 1463, 2018)
    Bounthavong, Mark
    Butler, Javed
    Dolan, Chantal M.
    Dunn, Jeffrey D.
    Fisher, Kathryn A.
    Oestreicher, Nina
    Pitt, Bertram
    Hauptman, Paul J.
    Veenstra, David L.
    PHARMACOECONOMICS, 2019, 37 (08) : 1071 - 1071
  • [36] Cost-Effectiveness of Dapagliflozin in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: the DELIVER Trial
    Lin, Lu
    Xiu, Qiu-ping
    Liu, Fei
    Zhang, Hou-jing
    Chen, Yi-feng
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 39 (2) : 297 - 305
  • [37] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Ghader Mohammadnezhad
    Behniya Azadmehr
    Mehdi Mirheidari
    Nazila Yousefi
    Cost Effectiveness and Resource Allocation, 20
  • [38] Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review
    Mohammadnezhad, Ghader
    Azadmehr, Behniya
    Mirheidari, Mehdi
    Yousefi, Nazila
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2022, 20 (01)
  • [39] Cost-Effectiveness Analysis of Sacubitril-Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction in Thailand
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2018, 18 (05) : 405 - 413
  • [40] Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis
    Zaca, Valerio
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2018, 19 (10) : 597 - 605
12345